DetailsCategory: DNA RNA and CellsPublished on Wednesday, 03 June 2020 09:39Hits: 523
Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA)
SEATTLE, WA and KING of PRUSSIA, PA, USA I June 2, 2020 I Seattle Children's Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases.
Initially, the alliance will focus on the development of treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome and X-linked Agammaglobulinemia. These are two of more than 400 identified primary immunodeficiency diseases in which a part of the body's immune system is missing or functions improperly.
"CSL Behring will collaborate with Seattle Children's experts to apply our novel gene therapy technology to their research pipeline, with an aim to address unmet needs for people living with certain rare primary immunodeficiency diseases," said Bill Mezzanotte, MD, Executive Vice President, Head of Research and Development for CSL Behring. "Expanding our gene therapy portfolio into an area of immunology well known to CSL exemplifies how we are strategically growing our capabilities in this strategic scientific platform and are collaborating with world class institutions to access innovation with the potential to vastly improve patients' lives."
"Stem cell gene therapies that correct the genetic abnormality driving a child's disease will transform the therapeutic options for children with Wiskott-Aldrich Syndrome, X-Linked Agammaglobulinemia and other immunodeficiency diseases,"said David J. Rawlings, MD, director of the Center for Immunity and Immunotherapies and division chief of immunology at Seattle Children's, and a professor of pediatrics and immunology at the University of Washington School of Medicine."The collaboration with CSL Behring supports our longstanding research programs for pediatric immunodeficiency diseases and will accelerate this research toward clinical trials, helping get these innovations to the children who need them."
CSL Behring researchers, working with researchers from Seattle Children's Research Institute, will investigate applying the proprietary platform technologies, Select+ and Cytegrity, to several pre-clinical gene therapy programs. These technologies, which have broad applications in ex vivo stem cell gene therapy, are designed to address some of the major challenges associated with the commercialization of stem cell therapy, including the ability to manufacture consistent, high-quality products, and to improve engraftment, efficacy and tolerability.
Wiskott-Aldrich Syndrome (WAS) has an estimated incidence between one and 10 cases per million males worldwide, according to the National Institutes of Health. WAS patients' immune systems function abnormally, making them susceptible to infections. They also experience eczema, autoimmunity and difficulty forming blood clots, leaving them vulnerable to life threatening bleeding complications. Today the only knowncurefor WAS is a stem cell transplant, if a suitable donor can be found.
X-linked Agammaglobulinemia (XLA) is another rare primary immunodeficiency in which patients have low levels of immunoglobulins (also known as antibodies), which are key proteins made by the immune system to help fight infections. Like WAS, XLA affects males almost exclusively, although females can be genetic carriers of the condition. While no cure exists for XLA, the goal of treatment is to boost the immune system by replacing missing antibodies and preventing or aggressively treating infections that occur, according to the Immune Deficiency Foundation.
About Seattle Children's
Seattle Children's mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children's Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.
Ranked as one of the top children's hospitals in the country by U.S. News & World Report, Seattle Children's serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho the largest region of any children's hospital in the country. As one of the nation's top five pediatric research centers, Seattle Children's Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children's Hospital and Research Foundation works with the Seattle Children's Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. Join Seattle Children's bold initiative It Starts With Yes: The Campaign for Seattle Children's to transform children's health for generations to come.
For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.
About CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people, and delivers its life-saving therapies to people in more than 70 countries. For more information, visit http://www.cslbehring.com and for inspiring stories about the promise of biotechnology, visit Vita http://www.cslbehring.com/Vita.
SOURCE: CSL Behring
- North Idaho resident working on a second chance at life - KREM.com - October 13th, 2022
- The Right-Wing Attempt to Control Higher Ed - The Chronicle of Higher Education - October 13th, 2022
- Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell Universal Donor Stem Cell for COVID-19 ARDS... - July 19th, 2022
- Hayden resident family determined to keep the fight against multiple sclerosis at home - KREM.com - July 19th, 2022
- Not Smart But Clever? The Return of 'Dumbphones' - WhoWhatWhy - March 25th, 2022
- Therapeutic Solutions International Reports Superior Neurogenesis Induction in Animal Model of Viral Induced Cognitive Dysfunction Compared to other... - August 18th, 2021
- Bodybuilder, 47, looks half his age & claims the trick to his youthful appearance & strength is thinking h... - The US Sun - July 21st, 2021
- Therapeutic Solutions International Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low... - April 29th, 2021
- Therapeutic Solutions International Uses StemVacs Platform to Generate Personalized Adoptive T Cell Therapy Targeting Cancer Stem Cells - PRNewswire - February 23rd, 2021
- What Nutritionists Need You to Know About Smoke Point and Cooking Oils - msnNOW - October 8th, 2020
- Dr. Dori Borjesson named dean of the WSU College of Veterinary Medicine - WSU News - January 25th, 2020
- In Utah, 'saving lives' with breast milk - FRANCE 24 - January 25th, 2020
- Oak Bay's top stories of 2019 - BCLocalNews - January 6th, 2020
- Robotics Industry Insights - Cobots, Raising the Human... - Robotics Online - Robotics Online - December 17th, 2019
- 100 hospitals and health systems with great orthopedic programs | 2019 - Becker's Hospital Review - December 7th, 2019
- Stem Cell Injections Shoulder | Cost of Stem Cell Therapy ... - September 10th, 2019
- News Releases - University of Idaho - May 16th, 2019
- Amniotic Stem Cell Injections, Advanced Muscle Integration ... - August 3rd, 2018
- Stem Cell Treatment Idaho | Stem Cell Treatment Sun Valley ... - September 21st, 2017
- Continuing the debate about right-to-die issues in Appleton - Idaho Statesman - September 4th, 2017
- FDA announces first US gene therapy approval for cancer treatment - East Idaho News - August 31st, 2017
- Idaho National Laboratory - Wikipedia - November 30th, 2016
- Stem Cell Therapy | Stem Cell Treatments | Idaho Falls ... - August 5th, 2016
- Stem cell clinics, FDA, and giant, unapproved for-profit ... - November 1st, 2015
- SlidePlayer - Upload and Share your PowerPoint presentations - November 1st, 2015
- Stem Cell Therapy For Treating Canine Osteoarthritis | The ... - October 19th, 2015
- Umbilical Cord Blood Stem Cells | CancerConnect News - October 1st, 2015
- Brain Facts - Dialogue for Kids (Idaho Public Television) - September 27th, 2015
- Stem Cells | Cornerstone Family Council - July 2nd, 2015
- PPT Stem Cell PowerPoint presentation | free to view ... - May 2nd, 2015
- Stem Cells - The ALS Association - January 17th, 2015
- Stem Cell Therapy For Autism In USA - World Stem Cells, LLC - December 12th, 2014
- COPD Stem Cell Treatment | Analytical Stem Cell - December 2nd, 2014
- Cancer stem cell - Wikipedia, the free encyclopedia - August 23rd, 2014
- Stem Cells and the Future of Regenerative Medicine - August 23rd, 2014
- Idaho Stem Cell Treatment | Stem Cell Treatments - August 22nd, 2014